Introduction
============

Pharyngeal cancer, the most prevalent malignant tumor in head and neck, tends to attack laryngeal mucous membranes ([@b1-ol-0-0-9375]). Currently, the pathogenesis of pharyngeal cancer is yet to be identified. In the 1990s, scholars initially segregated and identified non-metastasis 23 (nm 23) and later it was verified that the expression of nm 23 is closely correlated with the metastasis suppression in patients ([@b2-ol-0-0-9375]). Studies have shown that the expression product of nm 23 can directly affect the signal transduction system in cells and furthermore, have effects on the microfilaments and microtubules involved in biological activities of cells. In addition, it inhibits metastasis of tumor cells ([@b3-ol-0-0-9375],[@b4-ol-0-0-9375]). To date, although many scholars have reported the mechanism of nm 23 expression to inhibit metastasis of tumor cells, the study on the relation between nm 23 and prognoses of pharyngeal cancer patients remain controversial, and no agreement exists in the academic circle. In the present study, pharyngeal cancer patients diagnosed and treated from 2009 to 2012 were retrospectively analyzed. Immunohistochemical staining, quantitative-polymerase chain reaction (q-PCR) and western blotting were used to analyze the expression of nm 23 in different tissues. Besides, such patients were followed up for 5 years.

Patients and methods
====================

### Patients

A total of 122 pharyngeal cancer patients who were admitted to The Affiliated Hospital of Jining Medical College (Jining, China) from June 2009 to June 2012 were selected, and none received chemoradiotherapy preoperatively. There were 69 males and 53 females aged 39--78 years. Tumor node metastasis (TNM) staging indicated: 2 stage I cases, 21 stage II cases, 51 stage III cases and 48 stage IV cases; 23 stage T~1--2~ cases, 66 stage T~3~ cases, and 33 stage T~4~ cases. Histopathological grading showed: 16 stage I, 69 stage II, and 37 stage III cases. Moreover, there were 54 patients with lymphatic metastasis and 68 patients without lymphatic metastasis. Thirty normal pharyngeal mucosal tissues were taken as the control group. The patients or their family members signed the informed consent. The study was approved by the Ethics Committee of The Affiliated Hospital of Jining Medical College.

### Main reagents

Rabbit anti-human nm 23 (Dingguo Changsheng Biotechnology Co., Ltd., Beijing, China), goat anti-rabbit secondary antibody and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) internal reference antibody (Becton Dickinson; BD Biosciences, San Jose, CA, USA), diaminobenzidine (DAB) developer and citrate buffer powder (Xinyu Biotech, Shanghai, China), immunohistochemistry kit (DASF Bio, Nanjing, China), reverse transcription (RT) kit (Boyi Biotech, Shanghai, China), real-time quantitative fluorescent PCR kit (Vipotion Biotechnology Co., Ltd., Guangzhou, China), TRIGene reagent (GenStar BioSolutions Co., Ltd., Beijing, China), RT kit (Takera, Dalian, China), total protein extraction kit (KeyGen Biotech Co., Ltd., Nanjing, China) and bicinchoninic acid (BCA) protein assay kit (Nanjing Senbeijia Biotechnology Co., Ltd., Nanjing, China).

Methods
-------

### Immunohistochemical staining

Paraffin-embedded sections of two kinds of tissues were obtained, and after deparaffinating and hydration, phosphate-buffered saline (PBS) was used to wash the sections. In order to weaken the non-specific background staining caused by endogenous peroxidase, the foregoing sections were added with the blocking solution to block for 20 min and then, sealed by 10% serum for 10 min at room temperature. Afterwards, the primary antibody solution (diluted by 1:50), containing matrix metallopeptidase-9 monoclonal antibody (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1), was added for the overnight incubation at 4°C. Again, PBS was used to wash the resulting product and then, the secondary antibody solution (diluted by 1:50) was added for incubation at room temperature. The incubating products were washed using PBS 30 min later. After that, the sections were added with streptomycin avidin-peroxidase (SP) solution for 0.5 h of incubation at room temperature. After incubation, the foregoing sections were washed by PBS. Then, the sections were added with DAB developer for color development, washed by distilled water, counterstained and sealed for observation.

### Evaluation of immunohistochemical staining results

A field to be observed was randomly selected to count 100 cells, and the average of the cells in this field with nm 23 proteins positively expressed was calculated as the number of positive cells with nm 23 proteins positively expressed in tissues. Color brightness-based scoring: 0--3 points represented no dyeing, light yellow, brownish-yellow and tan, respectively. Scoring of the positive rate of stained cells: 0--4 points represented the percentages of positive cells - (1,10), (10,25), (25,50), (50,75) and (75,100), respectively. Finally, the foregoing two groups of scores were multiplied to obtain the final score: 0, (−); 1--4 points, (+); 5--8 points, (++) and 9--12 points, (+++).

### Expression of nm 23 messenger ribose nucleic acid (mRNA) determined via q-PCR

The primers were synthesized by Huamei Ruikang (Beijing) International Biotech Research Institute with the sequences shown in [Table I](#tI-ol-0-0-9375){ref-type="table"}. The total RNA in tissues was extracted according to the instructions of the total RNA extraction kit. The complementary deoxyribose nucleic acid (cDNA) was synthesized using reverse transcription kit.

Reaction solution (10 µl) contained: 2 µl 5X genomic DNA (gDNA) eraser buffer, 1 µl gDNA eraser, 1 µg total RNA and ribonuclease (RNase) free distilled water (dH~2~O).

RT system (20 µl) contained: 4 µl 5X PrimeScript Buffer, 1 µl PrimeScipt RT Enzyme Mix, 1 µl PrimeScript RT Enzyme Mix, 10 µl the foregoing reaction solution and 4 µl RNase-free dH~2~O. RT reaction condition: 37°C for 15 min and 85°C for 5 sec.

PCR system (25 µl) contained: 12.5 µl SYBR Premix Ex Taq™ II, 1 µl forward primer, 1 µl reverse primer, 2 µl cDNA and 8.5 µl dH~2~O. Reaction condition: Pre-degeneration for 3 min at 94°C, degeneration for 20 sec at 94°C, annealing for 20 sec at 58°C, and extension for 30 sec at 72°C, 40 cycles in total. GAPDH was taken as the internal reference. Real-time PCR instrument automatically calculated and displayed the relative mRNA expression level of nm 23.

### Expression of nm 23 proteins tested by western blotting

The total protein in the tissues was extracted according to the instructions of the total protein extraction kit, and BCA protein assay was performed to determine the concentration of the extracted proteins. Then, they were stored at −70°C for standby use. Gels at different concentrations were prepared for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-page). The corresponding positions of two proteins in gels were roughly confirmed based on markers and then, the proteins were transferred onto membranes for 35 min and sealed by 5% skim milk powder at 37°C. The proteins were added with the rabbit anti-human nm 23 and GAPDH polyclonal antibodies (diluted by 1:1,000; cat. no. 3345; Cell Signaling Technology, Danvers, MA, USA) 90 min later and incubated at 4°C overnight. The next day, the incubating products were added with Tris-buffered saline with Tween-20 (TBST) and placed on a shaking incubator to shake and wash 3 times (15 min each time). After that, the goat anti-rabbit secondary polyclonal antibody solution (diluted by 1:1,000; cat. no. 7074; Cell Signaling Technology) was added for 1 h of incubation at 37°C. When the incubation ended, TBST solution was added, and the sequent operations were performed as above. Afterwards, in a dark room, the enhanced chemiluminescent (ECL) fluid (Millipore Sigma, Burlington, MA, USA) was added to develop color, followed by exposure, development and fixation. Finally, ChemiDoc™ MP Imaging System was used to scan, and the professional image processing program of Image J was adopted to analyze images and record the absorbance value, with β-actin as the internal reference.

Statistical analysis. Statistical Product and Service Solutions (SPSS) 17.0, a professional statistics software (Beijing Xinmei Jiahong Technology Co., Ltd., Beijing, China), was used to analyze the data of the present study. The measurement data were expressed as mean ± standard deviation, and the one-way analysis of variance was used for inter-group comparisons and the post hoc test was Least Significant Difference test. GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) was adopted for the survival analysis. α=0.05 was taken as the statistical verification standard.

Results
=======

### Immumohistochemical staining

The immunohistochemical staining results showed that the positive expression rate of nm 23 in pharyngeal cancer tissues was 56.56% (69/122), while that in the normal laryngeal mucosal tissues was 90.00% (27/30). Differences between the two groups were statistically significant (p\<0.05) ([Fig. 1](#f1-ol-0-0-9375){ref-type="fig"} and [Table II](#tII-ol-0-0-9375){ref-type="table"}).

### Relationship between nm 23 expression and clinical features of pharyngeal cancer

The comparison of the nm 23 expression in pharyngeal cancer tissues with different pathological grades showed no obvious difference, without statistical significance (p\>0.05). In the the clinical staging, the expression rate (86.96%) in stage I--II cases was significantly higher than that (48.48%) in stage III--IV cases, with a statistically significant difference (p\<0.05). Similarly, that (75.00%) in cases without lymphatic metastasis was also obviously higher than that (37.78%) in cases with lymphatic metastasis, and the difference presented the statistical significance (p\<0.05) ([Table III](#tIII-ol-0-0-9375){ref-type="table"}).

### q-PCR results

The relative expression level of nm 23 mRNA in tissues was tested via q-PCR, and the results showed that the expression level of nm 23 mRNA in the normal pharyngeal mucosal tissues was significantly higher than that in the pharyngeal cancer tissues, with a statistically significant difference (p\<0.05) ([Fig. 2](#f2-ol-0-0-9375){ref-type="fig"}).

### Western blotting

Western blotting was conducted to detect the expression of nm 23 proteins. According to the result, the nm 23 proteins were significantly highly expressed in the normal pharyngeal mucosal tissues, and the difference from that in the pharyngeal cancer tissues was statistically significant (p\<0.05) ([Figs. 3](#f3-ol-0-0-9375){ref-type="fig"} and [4](#f4-ol-0-0-9375){ref-type="fig"}).

### Analysis of prognosis

The survival rate of patients with nm 23 protein positively expressed was higher than that of patients with the nm 23 protein negatively expressed. Especially in terms of 3-year survival rate, the survival rate of patients with the negative nm 23 protein expression was decreased to 12.96%, while that of patients with the positive expression reached up to 82.35% and began slowly decreasing. The difference between the two groups of patients presented a markedly statistical significance (p\<0.01) ([Fig. 5](#f5-ol-0-0-9375){ref-type="fig"}).

Discussion
==========

Since nm 23 was discovered in the 1990s, scholars all over the world have made a large number of systematic studies on the effects of nm 23 on various cancers ([@b5-ol-0-0-9375],[@b6-ol-0-0-9375]). Pharyngeal cancer patients often die of metastasis, and the metastasis of tumor is a very complex process, starting from the primary tumor cells infiltrating into the surrounding cytoplasmic matrix ([@b7-ol-0-0-9375],[@b8-ol-0-0-9375]). Currently, it is known that non-metastasis genes can participate in several steps of tumor cell metastasis process through various pathways and serve as one of natural defenders against the tumor metastasis in the body ([@b9-ol-0-0-9375],[@b10-ol-0-0-9375]). Pathological studies have shown that the lymphatic metastasis is one of the earliest incidents during metastasis and diffusion of most solid tumors in organic bodies and also one way of tumor metastasis ([@b11-ol-0-0-9375],[@b12-ol-0-0-9375]).

As a metabolic suppressor gene, nm 23 has been verified through many *in vitro* and *in vivo* experiments. Marioni *et al* ([@b13-ol-0-0-9375]) found that nm 23 can significantly suppress the cancerization of melanoma cells, such as inhibiting cell activity, tumor cell growth and distal infiltration and metastasis. Fang *et al* ([@b14-ol-0-0-9375]) reported according to the clinical examinations that the expression of nm 23 in the patients is significantly negatively correlated with the invasion and metastasis of tumor cells and has a marked effect on the prognoses of patients. According to the findings of He *et al* ([@b15-ol-0-0-9375]), the nm 23 mRNA expression level is significantly decreased in highly metastatic breast cancer tissues, but Han *et al* ([@b16-ol-0-0-9375]) studied the expression of nm 23 in thyroid tumors with the same technical method, and the results showed that although nm 23 in coding region is not mutated, there is no obvious negative correlation between the expression level of nm 23 and metastasis in thyroid tumor tissues. Therefore, it was inferred that the effects of nm 23 in different cancer tissues may vary to some degree. However, the effect of the nm 23 expression on pharyngeal cancer tissues remains controversial. It was found by Tong *et al* ([@b17-ol-0-0-9375]) that the lowly expressed nm 23 is closely correlated with the metastasis of pharyngeal cancer, while Fu *et al* ([@b18-ol-0-0-9375]) reported that the expression of nm 23 protein is not significantly correlated with the growth position and pathological grading of laryngeal cancer, but negatively correlated with lymphatic metastasis and clinical staging. On the contrary, some scholars held that the expression of nm 23 is positively correlated with lymphatic metastasis, but has no relation with clinical staging ([@b19-ol-0-0-9375]).

The retrospective analysis results of this study showed that the positive expression rate (90.00%) of nm 23 in the normal pharyngeal mucosal tissues was significantly higher than that (56.56%) in the pharyngeal cancer tissues, with a statistically significant difference (p\<0.05). The positive expression percentage (86.96%) of nm 23 in stage I--II cases was markedly higher than that (48.48%) in stage III--IV cases, with a statistically significant difference (p\<0.05). Similarly, that (75.00%) in cases without lymphatic metastasis was also obviously higher than that (37.78%) in cases with lymphatic metastasis, and there was a statistically significant difference (p\<0.05). This indicates that the expression of nm 23 proteins is significantly correlated with clinical staging of pharyngeal cancer and lymphatic metastasis. At the same time, it was indicated that at the gene and protein levels, the expression of nm 23 in the pharyngeal cancer tissues was significantly lower than that in the normal pharyngeal mucosal tissues (p\<0.05), which is consistent with the result of the study by Yang *et al* ([@b20-ol-0-0-9375]). According to the postoperative 5-year prognosis follow-up results of pharyngeal cancer patients, the survival rate of patients with nm 23 positive expression was significantly higher than that of patients with negative expression, and the difference showed a statistical significance (p\<0.01). Especially in terms of three-year survival rate, the survival rate of patients with nm 23 proteins negatively expressed was decreased to 12.96%, while that of patients with nm 23 proteins positively expressed reached up to 82.35%, indicating that the higher the positive expression of nm 23 is, the better the prognoses of pharyngeal cancer patients are.

In conclusion, the expression of nm 23 protein plays an important role in the occurrence, development and metastasis of pharyngeal cancer and may be regarded as one of the indicators to evaluate the prognoses of such patients.
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###### 

Primer sequences.

  Genes     Primer sequences
  --------- -------------------------------
  *nm 23*   F: 5′-GATGGCGAATCAGAGCTGGA-3′
            R: 5′-CATGCCACCGCCTATTGAAC-3′
  *GAPDH*   F: 5′-AGCGAGCATCCCCCAAAGTT-3′
            R: 5′-GGGCACGAAGGCTCATCATT-3′

F, forward; R, reverse.

###### 

Comparison of nm 23 expression in pharyngeal cancer tissues and normal pharyngeal mucosal tissues.

                                            nm 23 expression                          
  ----------------------------------- ----- ------------------ ---- ---- ---- ------- -------
  Laryngeal cancer tissues            122   53                 36   27   6    56.56   0.026
  Normal pharyngeal mucosal tissues   30    3                  7    5    15   90.00   

nm 23, non-metastasis 23.

###### 

Relations between the nm 23 expression and the clinical features of pharyngeal cancer.

  Groups                 No. of cases   Positive nm 23 expression n (%)   t-value   P-value
  ---------------------- -------------- --------------------------------- --------- ---------
  Sex                                                                     2.841     0.177
    Male                 69             45 (65.22)                                  
    Female               53             23 (43.40)                                  
  Age (year)                                                              3.115     0.082
    ≤60                  50             30 (60.00)                                  
    \>60                 72             38 (52.78)                                  
  Clinical staging                                                        8.452     0.037
    I--II                23             20 (86.96)                                  
    III--IV              99             48 (48.48)                                  
  Lymphatic metastasis                                                    10.793    0.021
    Yes                  45             17 (37.78)                                  
    No                   68             51 (75.00)                                  
  Pathological grading                                                    2.361     0.202
    I                    16             11 (68.75)                                  
    II                   69             39 (56.52)                                  
    III                  37             18 (48.65)                                  

nm 23, non-metastasis 23.
